Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin, a novel, first-in-class regulatory T cell stimulator for the treatment of, inter alia, alopecia areata.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at [phone].

What is the class period? February 26, 2025 – December 15, 2025

What are the allegations? Robbins LLP is Investigating Allegations that Nektar Therapeutics (NKTR) Overstated the Prospects of its REZOLVE-AA Trial

According to the complaint, during the class period, defendants failed to disclose that: (i) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Plaintiff alleges that on December 16, 2025, Nektar issued a press release during pre-market hours “announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin[.]” The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate. On this news, Nektar’s stock price fell $4.14 per share, or 7.77%, to close at $49.16 per share on December 16, 2025.

What can shareholders do now? You may be eligible to participate in the class action against Nektar Therapeutics. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Nektar Therapeutics settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.